Diagnostic and prognostic serum marker of cholangiocarcinoma (Review)

Zeng,Xiaojun; Tao,Hualin

doi:10.3892/ol.2014.2696

Diagnostic and prognostic serum marker of cholangiocarcinoma (Review)

Authors:
- Xiaojun Zeng
- Hualin Tao
View Affiliations

Affiliations: Department of Laboratory Medicine, Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China, Department of Laboratory Medicine, Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China
Published online on: November 10, 2014 https://doi.org/10.3892/ol.2014.2696
Pages: 3-8

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is a fatal disease that is typically diagnosed late and treated ineffectively. As the morbidity and mortality rates for CCA rise markedly, patietns with CCA currently have a poor prognosis. However, if it were possible to diagnose CCA early while effective treat methods are available, CCA patients would achieve a better quality of life. Therefore, preventing the process of CCA in the early stages is an urgent problem to solve. An accurate, quick and safe method to diagnose early‑stage CCA is required. The present review discusses the risk factors, status of research and certain serum markers of CCA. The sensitivity and specificity of these markers differ from each other. To explore the more accurate serum markers may be a novel direction and method for the diagnosis of CCA in laboratory medicine in the future.

View Figures

View References

1	Khan SA, Davidson BR, Goldin RD, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 61:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
2	Gentilini A, Rombouts K, Galastri S, et al: Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J Hepatol. 57:813–820. 2012. View Article : Google Scholar : PubMed/NCBI
3	Limpaiboon T: Epigenetic aberrations in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies. Asian Pac J Cancer Prev. 13:41–45. 2012.PubMed/NCBI
4	Boonjaraspinyo S, Wu Z, Boonmars T, Kaewkes S, et al: Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol Int. 61:145–150. 2012. View Article : Google Scholar
5	Buranrat B, Chau-in S, Prawan A, et al: NQO1 Expression Correlates with Cholangiocarcinoma Prognosis. Asian Pac J Cancer Prev. 13:131–136. 2012.PubMed/NCBI
6	Taylor-Robinson SD, Toledano MB, Arora S, et al: Increase in mortalityrates for intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 48:816–820. 2001. View Article : Google Scholar : PubMed/NCBI
7	Tanaka M, Tanaka H, Tsukuma H, et al: Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. Journal of Viral Hepatitis. 17:742–748. 2010. View Article : Google Scholar
8	Li M, Li J, Li P, et al: Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol. 27:1561–1568. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sempoux C, Jibara G, Ward SC, et al: Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis. 31:49–60. 2011. View Article : Google Scholar : PubMed/NCBI
10	Suarez-Munoz MA, Fernandez-Aguilar JL, Sanchez-Perez B, et al: Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol. 15:132–138. 2013. View Article : Google Scholar
11	Zhou Y, Zhou Q, Lin Q, et al: Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism. Int J Cancer. 15:1867–1875. 2013. View Article : Google Scholar
12	Sawanyawisuth K: Genes and cholangiocarcinoma. Southeast Asian J Trop Med Public Health. 40:701–712. 2009.PubMed/NCBI
13	Fava G: Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol. 15:12–22. 2010.
14	Briggs CD, Neal CP, Mann CD, et al: Prognostic molecular markers in cholangiocarcinoma: A systematic review. Eur J Cancer. 45:33–47. 2009. View Article : Google Scholar
15	Borger DR, Tanabe KK, Fan KC, et al: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 17:72–79. 2012. View Article : Google Scholar :
16	Subimerb C, Pinlaor S, Lulitanond V, et al: Circulating CD14+CD16+ monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol. 161:471–479. 2010. View Article : Google Scholar : PubMed/NCBI
17	Gu FM, Gao Q, Shi GM, et al: Intratumoral IL-17⁺ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 19:2506–2514. 2012. View Article : Google Scholar : PubMed/NCBI
18	Utispan K, Thuwajit P, Abiko Y, et al: Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 9:1–20. 2010. View Article : Google Scholar
19	Keeratichamroen S, Leelawat K, Thongtawee T, et al: Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. Int J Oncol. 39:873–881. 2011.PubMed/NCBI
20	Yonglitthipagon P, Pairojkul C, Chamgramol Y, et al: Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol. 40:1203–1212. 2010. View Article : Google Scholar : PubMed/NCBI
21	Khan SA, Davidson BR, Goldin R, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 51:1–9. 2002. View Article : Google Scholar
22	Li YG and Zhang N: Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Liver Dis. 41:605–608. 2009. View Article : Google Scholar : PubMed/NCBI
23	Leelawat K, Narong S, Wannaprasert J, et al: Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol. 16:4697–4703. 2010. View Article : Google Scholar : PubMed/NCBI
24	Singh S, Tang SJ, Sreenarasimhaiah J, et al: The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 56:2491–2496. 2011. View Article : Google Scholar : PubMed/NCBI
25	Jo JH, Chung MJ, Park JY, et al: High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study. Surg Endosc. 27:4210–4216. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wannhoff A, Hov JR, Folseraas T, et al: FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. 59:1278–1284. 2013.PubMed/NCBI
27	Sinakos E, Saenger AK, Keach J, et al: Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 9:434–439. 2011. View Article : Google Scholar : PubMed/NCBI
28	Liu SL, Song ZF, Hu QG, et al: Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 4:457–462. 2010. View Article : Google Scholar : PubMed/NCBI
29	Juntermanns B, Radunz S, Heuer M, et al: Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res. 15:357–361. 2010. View Article : Google Scholar : PubMed/NCBI
30	Silsirivanit A, Araki N, Wongkham C, et al: A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. Cancer. 117:3393–3403. 2011. View Article : Google Scholar : PubMed/NCBI
31	Sawanyawisuth K, Silsirivanit A, Kunlabut K, et al: A novel carbohydrate antigen expression during development of Opisthorchis viverrini-associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis. Parasitol Int. 61:151–154. 2012. View Article : Google Scholar
32	Silsirivanit A, Araki N, Wongkham C, et al: CA-S27: A novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Sci. 104:1278–1284. 2013. View Article : Google Scholar : PubMed/NCBI
33	Tao LY, Cai L, He XD, et al: Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 76:1210–1213. 2010.PubMed/NCBI
34	Leelawat K, Sakchinabut S, Narong S, et al: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol. 9:1–8. 2009. View Article : Google Scholar
35	Prakobwong S, Charoensuk L, Hiraku Y, et al: Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma. Int J Cancer. 131:E416–E424. 2012. View Article : Google Scholar
36	Brewer HB Jr, Fairwell T, LaRue A, et al: The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun. 80:623–630. 1978. View Article : Google Scholar : PubMed/NCBI
37	Wang X, Dai S, Zhang Z, et al: Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care (Engl). 18:625–635. 2009. View Article : Google Scholar
38	Leelawat K, Narong S, Wannaprasert J, et al: Serum NGAL to clinically distinguish cholangiocarcinoma from benign biliary tract diseases. Int J Hepatol. 2011:1–6. 2011. View Article : Google Scholar
39	Flower DR: The lipocalin protein family: structure and function. Biochem J. 318:1–14. 1996.PubMed/NCBI
40	Srisomsap C, Sawangareetrakul P, Subhasitanont P, et al: Proteomic Studies of Cholangiocarcinoma and Hepatocellular Carcinoma Cell Secretomes. J Biomed Biotechnol. 2010:1–18. 2010. View Article : Google Scholar
41	Jie Z, Cai Y, Yang W, et al: Protective effects of α1-antitrypsin on acute lung injury inrabbits induced by endotoxin. Chin Med J (Engl). 116:1678–1682. 2003.
42	Jamnongkan W, Techasen A, Thanan R, et al: Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma. Tumour Biol. 34:695–704. 2013. View Article : Google Scholar
43	Sriwanitchrak P, Viyanant V, Chaijaroenkul W, et al: Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev. 12:1503–1510. 2011.PubMed/NCBI
44	Tang W, Inagaki Y, Kokudo N, et al: KL-6 mucin expression in carcinoma of the ampulla of Vater: Association with cancer progression. World J Gastroenterol. 11:5450–5454. 2005.PubMed/NCBI
45	Xu H, Inagaki Y, Tang W, et al: Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma. Hepatogastroenterology. 55:2000–2004. 2008.
46	Khoontawad J, Hongsrichan N, Chamgramol Y, et al: Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma. Tumour Biol. 35:1029–1039. 2013. View Article : Google Scholar : PubMed/NCBI
47	Tian M, Cui YZ, Song GH, et al: Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 8:1–11. 2008. View Article : Google Scholar
48	Jackson D, Craven RA, Hutson RC, et al: Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res. 13:7370–7379. 2007. View Article : Google Scholar : PubMed/NCBI
49	Dieplinger H, Ankerst DP, Burges A, et al: Afamin and Apolipoprotein A-IV: Novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 18:1127–1133. 2009. View Article : Google Scholar : PubMed/NCBI
50	Dieplinger B, Egger M, Gabriel C, et al: Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma. Clin Chim Acta. 425:236–241. 2013. View Article : Google Scholar : PubMed/NCBI
51	Tolek A, Wongkham C, Proungvitaya S, et al: Serum α1β-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med (Maywood). 237:1142–1149. 2012. View Article : Google Scholar
52	Zhang X, Xiao Z, Liu X, et al: The potential role of ORM2 in the development of colorectal cancer. PLoS One. 7:1–7. 2012.
53	Nagahara M, Nishida N, Iwatsuki M, et al: Kinesin 18A expression: clinical relevance to colorectal cancer progression. Int J Cancer. 129:2543–2552. 2011. View Article : Google Scholar : PubMed/NCBI
54	Rucksaken R, Khoontawad J, Roytrakul S, et al: Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma. Cancer Biomark. 12:81–95. 2012.
55	Wang Y, Zhou B, Li J, et al: Inhibitors of 5-lipoxygenase inhibit expression of intercellular adhesion molecule-1 in human melanoma cells. Acta Pharmacol Sin. 25:672–677. 2004.PubMed/NCBI
56	Touvier M, Fezeu L, Ahluwalia N, et al: Pre-diagnostic levels of adiponectin and soluble vascular cell adhesion molecule-1 are associated with colorectal cancer risk. World J Gastroenterol. 18:2805–2812. 2012. View Article : Google Scholar : PubMed/NCBI
57	Song WB, Lv YH, Zhang ZS, et al: Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J Gastroenterol. 15:3916–3919. 2009. View Article : Google Scholar : PubMed/NCBI
58	Janan M, Proungvitaya S, Limpaiboon T, et al: Serum adhesion molecule-1 (icam-1) as a potential prognostic marker for cholangiocarcinoma patients. Asian Pac J Cancer Prev. 13:107–114. 2012.PubMed/NCBI
59	Schneider J, Bitterlich N and Schulze G: Improved sensitivity in the diagnosis of gastro-intestinal tumors by Fuzzy Logic-based tumor marker profiles including the tumor M2-PK. Anticancer Res. 25:1507–1515. 2005.PubMed/NCBI
60	Yin L, Wang X, Luo C, et al: The value of expression of M2-PK and VEGF in patients with advanced gastric cancer. Cell Biochem Biophys. 67:1033–1039. 2013. View Article : Google Scholar : PubMed/NCBI
61	Koss K, Harrison RF, Gregory J, et al: The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett’s oesophagus. J Clin Pathol. 57:1156–1159. 2004. View Article : Google Scholar : PubMed/NCBI
62	Wu G, Bazer FW, Burghardt RC, et al: Proline and hydroxyproline metabolism: implications for animal and human nutrition. Amino Acids. 40:1053–1063. 2011. View Article : Google Scholar
63	Jagtap VR and Ganu JV: Effect of antiresorptive therapy on urinary hydroxyproline in postmenopausal osteoporosis. Indian J Clin Biochem. 27:90–93. 2012. View Article : Google Scholar :
64	Kristiansen TZ, Harsha HC, Grønborg M, et al: Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res. 7:4670–4677. 2008. View Article : Google Scholar : PubMed/NCBI
65	Li W, Wang X, Li B, et al: Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer. Urology. 80:e1–e7. 2012. View Article : Google Scholar
66	Chen MH, Jan YH, Chang PM, et al: Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann Surg Oncol. 20:616–624. 2013. View Article : Google Scholar
67	Beyazit Y, Purnak T, Suvak B, et al: Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res Hepatol Gastroenterol. 35:644–649. 2011. View Article : Google Scholar : PubMed/NCBI
68	Liu JB, Yu ZP, Zhao WZ, et al: Liquid chromatographic assay of peptides activity with inhibiting angiotensin converting enzyme. Chem Res Chin Univ. 26:712–716. 2010.
69	Kósa JP, Horváth P, Wölfling J, et al: CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells. World J Gastroenterol. 19:2621–2628. 2013. View Article : Google Scholar : PubMed/NCBI
70	Kennedy L, Baker K, Hodges K, et al: Dysregulation of vitamin D3 synthesis leads to enhanced cholangiocarcinoma growth. Dig Liver Dis. 45:316–322. 2013. View Article : Google Scholar : PubMed/NCBI
71	Hunsawong T, Singsuksawat E, In-chon N, et al: Estrogen is increased in male cholangiocarcinoma patients’ serum and stimulates invasion in cholangiocarcinoma cell lines in vitro. J Cancer Res Clin Oncol. 138:1311–1320. 2012. View Article : Google Scholar : PubMed/NCBI
72	Yin X, Zheng SS, Zhang BH, et al: Elevation of serum c-glutamyltransferase as a predictorn of aggressive tumor behaviors and unfavorable prognosis in patients with intrahepatic cholangiocarcinoma: analysis of a large monocenter study. Eur J Gastroenterol Hepatol. 25:1408–1414. 2013. View Article : Google Scholar : PubMed/NCBI
73	Forrest LM, McMillan DC, McArdle CS, et al: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030. 2003. View Article : Google Scholar : PubMed/NCBI
74	Oshiro Y, Sasaki R, Fukunaga K, et al: Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 20:389–395. 2013. View Article : Google Scholar
75	Specht S, Isse K, Nozaki I, et al: SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis. Clin Exp Metastasis. 30:877–890. 2013. View Article : Google Scholar : PubMed/NCBI
76	Sato Y, Harada K, Sasaki M, et al: Heat shock proteins 27 and 70 are potential biliary markers for the detection of cholangiocarcinoma. Am J Pathol. 180:123–130. 2012. View Article : Google Scholar